Accessibility Menu
PharmaCielo logo

PharmaCielo(TSXV) PCLO

Market CapCA$12.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-99%
5 Year-95%
1 Year+33%
1 Month-8%
CA$0.06
+0.00%
+0.00Today
PharmaCielo last closing stock price
MetricPriceDate
Last closeCAD 0.062026-08-14
PharmaCielo stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-20%CAD 0.082026-08-07
1 month-7.69%CAD 0.072026-07-15
3 month-33.33%CAD 0.092026-05-15
Year to date+33.33%CAD 0.052025-08-05
1 year+33.33%CAD 0.052025-08-05
3 year-52%CAD 0.132023-08-15
5 year-95.45%CAD 1.322021-08-13
Since inception-98.97%CAD 5.852019-01-18

PharmaCielo Financials at a Glance

Market Cap

CA$12.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$2.54M

Net Income (TTM)

-CA$3.58M

EPS (TTM)

-CA$0.02

P/E Ratio

-3.23

Dividend

CA$0.00

Beta (Volatility)

-0.17 (Low)

Price

CA$0.06

Volume

300

Open

CA$0.06

Previous Close

CA$0.06

Daily Range

CA$0.06 - CA$0.06

52-Week Range

CA$0.04 - CA$0.17

Estimated Earnings Date

Jul 30, 2026

PCLO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PharmaCielo

PharmaCielo Ltd. is a leading company in the cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts. The company operates primarily in Canada and Colombia, serving a diverse clientele that includes health and wellness product manufacturers, pharmacies, and medical clinics.

Products and Services
  • Pharmaceutical-grade cannabis extracts, including THC and CBD products
  • Telemedicine software solutions for healthcare providers
  • Partnerships with health and wellness manufacturers for product development
Growth Outlook
  • Expansion into new markets is anticipated to drive revenue growth
  • Strategic partnerships are expected to enhance product offerings
  • Increasing demand for cannabis-based products supports long-term growth potential
Financial Highlights
  • Recent quarterly revenue of 718,514 CAD shows a positive trend
  • Trailing twelve months (TTM) revenue indicates a significant increase compared to previous periods
  • Operating cash flow improved, reflecting better management of working capital
PharmaCielo Ltd. is positioned in a rapidly growing industry, with a focus on high-quality cannabis products and innovative technology solutions. The company's strategic initiatives and partnerships are designed to capitalize on the increasing demand for cannabis-based products, which is expected to drive future growth. Recent financial performance indicates a positive trajectory, with improvements in revenue and cash flow management. As the market for cannabis continues to expand, PharmaCielo aims to leverage its expertise and resources to enhance its competitive position.
AI Generated • Aug 4, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Marc Lustig, MBA

Website

www.pharmacielo.com

Headquarters

Toronto, ON M5C 1P1, CA

PCLO Financials

Key Financial Metrics (TTM)

Gross Margin

29.56%

Operating Margin

-127.52%

Net Income Margin

-141.06%

Return on Equity

27.36%

Return on Capital

-116.13%

Return on Assets

-28.47%

Earnings Yield

-30.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$12.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

211.28M

Volume

300

Avg. Volume

44.14K

Financials (TTM)

Gross Profit

CA$749.82K

Operating Income

-CA$3.23M

EBITDA

-CA$402.27K

Operating Cash Flow

-CA$4.61M

Capital Expenditure

CA$9.00

Free Cash Flow

-CA$4.61M

Cash & ST Invst.

CA$17.52K

Total Debt

CA$19.14M

PharmaCielo Performance Analysis

PharmaCielo annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31CAD 1,541,749-71.0%
20242024-12-31CAD 3,479,797125.7%
20252025-03-31CAD 3,173,318-8.8%
20262026-03-31CAD 2,536,235-20.1%
PharmaCielo sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-59.3%
Q32025-09-30175.6%
Q42025-12-31-31.8%
Q12026-03-3118.5%
PharmaCielo annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31CAD -0.105.8%
20242024-12-31CAD -0.05-47.5%
20252025-03-31CAD -0.0722.1%
20262026-03-31CAD -0.02-70.9%
PharmaCielo sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3046.9%
Q32025-09-30-7.2%
Q42025-12-31129.7%
Q12026-03-31-395.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$718.51K

-9.4%

Gross Profit

CA$112.15K

-5.5%

Gross Margin

15.61%

N/A

Market Cap

CA$12.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$47.30K

N/A

Employees

268

N/A

Net Income

-CA$1.30M

+42.9%

EBITDA

-CA$497.20K

+54.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$17.52K

-67.6%

Total Debt

CA$19.14M

-13.9%

Accounts Receivable

CA$889.59K

-7.2%

Inventory

CA$1.96M

+43.9%

Long Term Debt

CA$0.00

-100.0%

Short Term Debt

CA$19.14M

+8.7%

Return on Assets

-28.47%

N/A

Return on Invested Capital

29.45%

N/A

Free Cash Flow

-CA$3.73M

-2625.0%

Operating Cash Flow

-CA$3.73M

-2624.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KHRN.VKhiron Life Sciences Corp.
CA$0.04+0.00%
VIVO.TOVIVO Cannabis Inc.
CA$0.03+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About PCLO

What is the current price of PharmaCielo?

PharmaCielo is trading at CA$0.06 per share.

What is the 52-week range for PharmaCielo?

Over the past 52 weeks, PharmaCielo has traded between CA$0.04 and CA$0.17.

How much debt does PharmaCielo have?

As of the most recent reporting period, PharmaCielo reported total debt of CA$19.14M.

How much cash does PharmaCielo have on hand?

PharmaCielo reported CA$17.52K in cash and cash equivalents in its most recent financial results.

What is PharmaCielo’s dividend yield?

PharmaCielo does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services